Description
Cagrilintide is a long-acting synthetic analogue of amylin, a pancreatic peptide hormone that is co-secreted alongside insulin [6]. Structurally engineered to extend the duration of receptor engagement relative to native amylin, cagrilintide belongs to a class of investigational peptides that interact with amylin receptors involved in satiety signaling and metabolic regulation [4]. Its chemical design incorporates modifications that confer greater plasma stability and a prolonged pharmacokinetic profile compared with the endogenous hormone [5].
Within preclinical and controlled research settings, the compound has been studied for its interactions with neuroendocrine pathways governing appetite, energy homeostasis, and metabolic signaling. Phase 2 investigation demonstrated a dose-dependent relationship between cagrilintide administration and changes in metabolic endpoints across several dose levels ranging from 0.3 mg to 4.5 mg in participants enrolled in controlled trials [4]. These early findings generated substantial interest in characterizing the molecule's receptor-binding dynamics and downstream signaling consequences.
More recent Phase 3a research has examined cagrilintide both as a monotherapy and as a component of the fixed combination known as CagriSema, co-administered with the GLP-1 receptor agonist semaglutide [1][3]. Network meta-analyses have positioned CagriSema within the broader landscape of incretin-based and amylin-based research tools, noting its distinct mechanistic profile relative to GLP-1 receptor agonists acting alone [2]. This dual-receptor research model has made cagrilintide a subject of particular interest for investigators studying the intersection of amylin and GLP-1 signaling axes in metabolic biology.
References
[1] Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 2025. https://pubmed.ncbi.nlm.nih.gov/40544433/
[2] Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2024. https://pubmed.ncbi.nlm.nih.gov/38286487/
[3] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine, 2025. https://pubmed.ncbi.nlm.nih.gov/40544432/
[4] Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England), 2021. https://pubmed.ncbi.nlm.nih.gov/34798060/
[5] CAGRILINTIDE (ChEMBL4802169). ChEMBL, European Bioinformatics Institute. https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4802169/
[6] Cagrilintide. Wikipedia. https://en.wikipedia.org/wiki/Cagrilintide
